Shopping Cart 0
Cart Subtotal
USD 0

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Pipeline Review, H2 2017

Summary

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The latest report Integrin Beta 7-Pipeline Review, H2 2017, outlays comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interactions involve the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. It binds to HIV-1 gp120 that allows the virus to enter GALT (major trigger of AIDS disease). The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 1 and 2 respectively. Report covers products from therapy areas Gastrointestinal, Infectious Disease, Immunology and Oncology which include indications Ulcerative Colitis, Crohn Disease (Regional Enteritis), Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammatory Bowel Disease, Celiac Disease, Graft Versus Host Disease (GVHD) and Melanoma.

Furthermore, this report also reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)

The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Overview

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Companies Involved in Therapeutics Development

Genentech Inc

Protagonist Therapeutics Inc

Takeda Pharmaceutical Company Ltd

Viriom Inc

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Drug Profiles

ET-3764-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etrolizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PTG-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vedolizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VM-4500-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Dormant Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Discontinued Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Product Development Milestones

Featured News & Press Releases

May 09, 2017: Provincial drug plans, including Ontario and BC, make ENTYVIO (vedolizumab) available to treat inflammatory bowel disease

May 08, 2017: New Real-World Analyses Support Effectiveness and Safety of Entyvio (vedolizumab) for Ulcerative Colitis and Crohns Disease

Feb 17, 2017: Five-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn;s and Colitis Organisation (ECCO) Provides Information on the Long-Term Use of Vedolizumab in Adult Patients with Moderate to Severely Active Ulcerative Colitis and Crohn's Disease

Feb 17, 2017: Protagonist Therapeutics Presents Data on Oral Peptide Drug Candidate PTG-100 at European Crohn's and Colitis Organization Congress

Jan 17, 2017: Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis

Jan 05, 2017: Key Patent is Issued Covering Protagonist Therapeutics' Alpha4Beta7 Integrin Peptide Inhibitors including Oral Drug Candidate PTG-100

Dec 09, 2016: GEMINI II & III Post-hoc Analysis Reports Clinical Benefits of Vedolizumab as Induction and Maintenance Therapy in Tumor Necrosis Factor-Naive Patients with Moderately to Severely Active Crohns Disease

Dec 08, 2016: Takeda Presents 17 Abstracts at the 2016 Advances in Inflammatory Bowel Diseases (AIBD) Annual Conference

Nov 24, 2016: Takeda's ENTYVIO (vedolizumab) receives positive reimburement recommendation from Common Drug Review for treatment of Crohns Disease

Nov 23, 2016: Takeda IBD Treatment ENTYVIO (vedolizumab) Receives Prestigious Prix Galien Canada Innovative Product Award

Oct 17, 2016: Takeda Presents Real-World Vedolizumab Data in Ulcerative Colitis and Crohn's Disease at 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting

Oct 17, 2016: Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies

Oct 13, 2016: Scientists at NIH and Emory achieve sustained SIV remission in monkeys

Oct 13, 2016: Protagonist Therapeutics to Present Phase 1 Clinical and Preclinical Data on PTG-100 at UEG Week, Vienna

Oct 12, 2016: PROMETHEUS Anser VDZ Test Validated For Use in Inflammatory Bowel Disease Patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Genentech Inc, H2 2017

Pipeline by Protagonist Therapeutics Inc, H2 2017

Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Pipeline by Viriom Inc, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Therapeutic Products under Development, Key Players in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Therapeutics, Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Pipeline Overview, Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Pipeline, Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Pipeline Assessment


Companies

Genentech Inc

Protagonist Therapeutics Inc

Takeda Pharmaceutical Company Ltd

Viriom Inc

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Pipeline Review, H2 2017

Summary

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies. The latest report Integrin Beta 7-Pipeline Review, H2 2017, outlays comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Integrin beta-7 is an integrin protein encoded by the ITGB7 gene. It interacts with the cell surface adhesion molecules MADCAM1 which is normally expressed by the vascular endothelium of the gastrointestinal tract. Interactions involve the tripeptide L-D-T in MADCAM1, and L-D-V in fibronectin. It binds to HIV-1 gp120 that allows the virus to enter GALT (major trigger of AIDS disease). The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 1 and 2 respectively. Report covers products from therapy areas Gastrointestinal, Infectious Disease, Immunology and Oncology which include indications Ulcerative Colitis, Crohn Disease (Regional Enteritis), Human Immunodeficiency Virus (HIV) Infections (AIDS), Inflammatory Bowel Disease, Celiac Disease, Graft Versus Host Disease (GVHD) and Melanoma.

Furthermore, this report also reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)

The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects

The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Overview

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Companies Involved in Therapeutics Development

Genentech Inc

Protagonist Therapeutics Inc

Takeda Pharmaceutical Company Ltd

Viriom Inc

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Drug Profiles

ET-3764-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etrolizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PTG-100-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vedolizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VM-4500-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Dormant Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Discontinued Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)-Product Development Milestones

Featured News & Press Releases

May 09, 2017: Provincial drug plans, including Ontario and BC, make ENTYVIO (vedolizumab) available to treat inflammatory bowel disease

May 08, 2017: New Real-World Analyses Support Effectiveness and Safety of Entyvio (vedolizumab) for Ulcerative Colitis and Crohns Disease

Feb 17, 2017: Five-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn;s and Colitis Organisation (ECCO) Provides Information on the Long-Term Use of Vedolizumab in Adult Patients with Moderate to Severely Active Ulcerative Colitis and Crohn's Disease

Feb 17, 2017: Protagonist Therapeutics Presents Data on Oral Peptide Drug Candidate PTG-100 at European Crohn's and Colitis Organization Congress

Jan 17, 2017: Protagonist Therapeutics Initiates Phase 2b Study of Oral Drug Candidate PTG-100 in Ulcerative Colitis

Jan 05, 2017: Key Patent is Issued Covering Protagonist Therapeutics' Alpha4Beta7 Integrin Peptide Inhibitors including Oral Drug Candidate PTG-100

Dec 09, 2016: GEMINI II & III Post-hoc Analysis Reports Clinical Benefits of Vedolizumab as Induction and Maintenance Therapy in Tumor Necrosis Factor-Naive Patients with Moderately to Severely Active Crohns Disease

Dec 08, 2016: Takeda Presents 17 Abstracts at the 2016 Advances in Inflammatory Bowel Diseases (AIBD) Annual Conference

Nov 24, 2016: Takeda's ENTYVIO (vedolizumab) receives positive reimburement recommendation from Common Drug Review for treatment of Crohns Disease

Nov 23, 2016: Takeda IBD Treatment ENTYVIO (vedolizumab) Receives Prestigious Prix Galien Canada Innovative Product Award

Oct 17, 2016: Takeda Presents Real-World Vedolizumab Data in Ulcerative Colitis and Crohn's Disease at 2016 American College of Gastroenterology (ACG) Annual Scientific Meeting

Oct 17, 2016: Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies

Oct 13, 2016: Scientists at NIH and Emory achieve sustained SIV remission in monkeys

Oct 13, 2016: Protagonist Therapeutics to Present Phase 1 Clinical and Preclinical Data on PTG-100 at UEG Week, Vienna

Oct 12, 2016: PROMETHEUS Anser VDZ Test Validated For Use in Inflammatory Bowel Disease Patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indication, H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Genentech Inc, H2 2017

Pipeline by Protagonist Therapeutics Inc, H2 2017

Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017

Pipeline by Viriom Inc, H2 2017

Dormant Projects, H2 2017

Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Therapeutic Products under Development, Key Players in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Therapeutics, Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Pipeline Overview, Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Pipeline, Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Pipeline Assessment


Companies

Genentech Inc

Protagonist Therapeutics Inc

Takeda Pharmaceutical Company Ltd

Viriom Inc